DVT needs to be more accurately categorized ... Techniques for thrombus removal include catheter-directed thrombolysis, mechanical thrombectomy and various combinations of both (pharmacomechanical ...

An assessment of essential considerations for clinicians adopting new DVT tools, focusing on efficacy, safety, and ...

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after ...

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Image Source: Zacks Investment Research NARI’s ClotTriever system is anFDA 510(k)-cleared and CE-Marked mechanical thrombectomy device specifically designed for the treatment of DVT. The 500 ...

Stryker said it has a definitive agreement to purchase Inari Medical for $80 per share, a big premium that values the deal at $4.9 billion.

Thrombectomy Devices Market Drivers: . The growing prevalence of conditions like DVT, PE, and ischemic strokes increases demand for thrombectomy devices. . Innovations in thrombectomy devices ...

Penumbra (PEN) stock rises as Stryker (SYK) agrees to acquire its rival in the thrombectomy market, Inari Medical (NARI) for $4.9B in cash. Read more here.

1,2,3 ClotTriever is the most studied thrombectomy device for DVT, including the ongoing Randomized Controlled Trial, DEFIANCE, comparing ClotTriever to anticoagulation alone for patients with DVT.

MT’s share would rise to around 50% in DVT and about 60% in PE. The Alameda, California-based company is likely to gain market share in the mechanical thrombectomy (MT) segment, according to ...

If the IF DVT was related to a major reversible risk ... [24,36] Percutaneous mechanical thrombectomy (Trerotola and Angiojet®) When thrombolytics are absolutely contraindicated Removes thrombus ...